GENE ONLINE|News &
Opinion
Blog

2022-06-27|

Amai Proteins, producer of 100% protein sweetener that reduces sugar in Food & Beverages by up to 70%, voted Global Winner at the 2022 Extreme Tech Challenge Competition

by GeneOnline
Share To
 

PALO ALTO, Calif., June 28, 2022 /PRNewswire/ — Amai Proteins, an Israeli start-up developer of novel designer proteins that answer the needs of consumers and industry, is the Global Winner of the 2022 XTC competition. Extreme Tech Challenge (XTC) is the world’s largest start-up competition for purpose-driven companies. Over 2000+ start-ups from 100+ countries competed in 10 impact areas ranging from Biotech to Education, Fintech to Cleantech, etc.

Sugar overconsumption underlies the Metabolic Syndrome (obesity, diabetes, and more), a global health challenge primarily affecting the lower socioeconomic classes. Sugar production also places a significant burden on arable land and water usage, contributing air, land, and sea pollution.

Dr. Ilan Samish, CEO and Founder said: “Amai – ‘sweet’ in Japanese – produces a great tasting and market-fit 100% protein sweetener via Amai’s Pro3 Platform: Pro-Design AI-CPD (Computational Protein Design), Pro-Planet precision fermentation, and Pro-Taste food technology.

Our first product, sweelinTM, is a sustainable, 100% sweet protein that can reduce 40% to 70% of added sugar in a wide variety of food & beverages, without changing the consumer taste experience. The novel proteins mimic proteins that reside in harsh conditions (e.g., Dead Sea, hot springs, acidic swamps) and are thus fit for the requirements for the mass food market. These include soft drinks, fruit juices, dairy, alternative dairy products, sauces, spreads, snacks, ketchup, chocolate, peanut butter, energy bars, functional foods, and much more.

Amai’s sweelinTM combines cost-effectiveness with significant impact improvements both for the health of our people and the health of our planet.”

About Amai Proteins
Amai Proteins develops novel designer proteins that answer the needs of consumers and industry. The first product, sweelinTM, is a 100% sweet protein designed to significantly replace sugar and sugar alternatives in a wide variety of food & beverages including soft drinks, fruit juice, dairy products, sauces, spreads, dressings, snacks, peanut butter, and much more. Our solutions are inspired by nature and built with biology through a natural fermentation process. With our Pro3 platform, Amai Proteins aims to create future breakthroughs in the world of meat, plant, and milk proteins.

To learn more visit: www.amaiproteins.com, visit our official LinkedIn and YouTube channels. 

About XTC Extreme Tech Challenge
TECH FOR PURPOSE: XTC is a non-profit organization behind the world’s biggest startup competition that aims to help startups change the world for the better. In our quest, we are supported by leading corporations, VCs, foundations, policymakers, universities, and tech conferences. The Extreme Tech Challenge impact competition assesses startups around the world with a focus on the 17 Sustainability Development Goals (SDGs) set by the United Nations along with other criteria – level of innovation, market fitness and team quality. The Extreme Tech Challenge 2022 Global Finals presented by TechCrunch Session Climate was attended by an audience of 1600+ in person and remote attendees.
https://extremetechchallenge.org 

For more information:
Dr. Ilan Samish, Founder & CEO, Amai Proteins
ilan.samish@amaiproteins.com

 

Dr. Ilan Samish (right), founder and CEO at Amai Proteins, Grand Winner of the Extreme Tech Challenge XTC 2022 competition.
Dr. Ilan Samish (right), founder and CEO at Amai Proteins, Grand Winner of the Extreme Tech Challenge XTC 2022 competition.

 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Infinitopes’ Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
2024-05-09
Lunit AI Solutions to Power Samsung’s X-ray Devices for Advanced Chest Screening
2024-01-16
FDA Keynote Speaker in the Spotlight, CAR-T Industry Leaders Gather for Discussion-Join the 2024 GenScript Biotech Global Forum for a New Journey in Cell and Gene Therapy
2023-12-24
LATEST
Revolutionizing Treatment: ASGCT’s Clinical Trials Spotlight on Immunotherapy, Cancer Vaccines, and Auditory Diseases
2024-05-09
Advancing Health: ASGCT’s Clinical Trials Spotlight on Cell Therapy and Cell-Based Gene Therapy
2024-05-09
Infinitopes’ Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
2024-05-09
Profluent Achieves Human Genome Editing Milestone Using OpenCRISPR-1: The First AI-Generated, Open-Source Gene Editor
2024-05-08
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
EVENT
Scroll to Top